In pharma and life sciences, the scarce skill sets the price of the hire.
Pharma and life sciences enter 2026 as one of the strongest pay markets in India. Pharmaceuticals are projected to increment 10.1% this year and clinical research organisations 10.2%, both ahead of the 9.1% India average. The story sits at the senior end: GCC expansion, global R&D mandates and a thin senior-science pool are pushing offers up, fastest in regulatory, clinical, biostatistics and computational-bio roles. Pharma GCCs now set the senior price, paying up to around 20% more than IT-services firms for the same skill. This edition reads where the money sits by role and city, what the scarce skills cost, and what an offer needs to clear to land the hire.
What the pharma pay data is actually saying.
Five findings worth surfacing this edition. The full report carries the role-by-role salary bands, the skill-scarcity matrix and the city read behind them; these are the ones we'd flag in a leadership conversation.
Entry pay is rigid, the senior end breaks.
The GCC premium decides who you can attract.
The scarce skill sets the premium.
Pharma and CROs sit near the top of the pay table.
Hyderabad is the fastest-growing pharma GCC base.
Pharma, life sciences and CROs all clear the India average.
Projected salary increment by sector for 2026, across India. Pharmaceuticals, life sciences and CROs all clear the 9.1% India average; the GCCs lead the table while IT services trail at 6.9%.
Hiring against this shortage? We run the search.
Regulatory affairs, clinical research, biostatistics and computational-bio leadership across pharma GCCs and top CROs. If you're pricing a scarce senior science skill against a thin pool, this is the desk that lands the hire.
What's inside this edition.
Sequenced so CHROs and talent leaders get the strategic read up top, and the working bands and tables underneath; built to skim in minutes and use the same day.
This edition draws on Recruise's own placement data and pay benchmarking (proprietary) for the salary bands and the scarce-skill premium read, corroborated with public sources: Deloitte India Talent Outlook 2026 for the sector increments, EY Future of Pay 2026 for the GCC 10.4% increment, and Aon, NASSCOM, PayScale, AmbitionBox and Glassdoor (public), to June 2026. Salary bands are fixed CTC in INR lakhs per annum, indicative public market ranges; senior science roles in GCCs and top CROs sit at the upper end while domestic mid-market pharma sits lower, and bands vary with company size and location.
Get the next Compensation Index the day it drops.
One Tuesday email. The latest Compensation Index PDF in the first link, one observation from Sachith underneath. Plus the Talent Radar and Hiring Pulse in their respective months.
